Search clinical trials for: MVA (smallpox vaccine)

Total 7251 results

National Institute of Allergy and Infectious Diseases...

Completed

Combination Study With MVA BN and Dryvax

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

ACAM 3000 MVA at Harvard Medical School

Smallpox

United States
Ivan Litvinov

Terminated

Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer (MUSIC-01)

Basal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin Cancer

Canada
National Institute of Allergy and Infectious Diseases...

Completed

Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

Smallpox

United States
Sanofi Pasteur, a Sanofi Company

Terminated

Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive

HIV Infections | Smallpox

United States
Sanofi Pasteur, a Sanofi Company

Withdrawn

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

Atopic Dermatitis | Smallpox

United States
Sanofi Pasteur, a Sanofi Company

Completed

Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine

Smallpox
National Institute of Allergy and Infectious Diseases...

Completed

Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

Smallpox

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

Yellow Fever | Yellow Fever Immunisation

United States
Bavarian Nordic

Completed

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

Smallpox

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique...

Recruiting

Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC

Monkeypox

Congo, The Democratic Republic of the
Emergent BioSolutions

Completed

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

Smallpox

United States
Centers for Disease Control and Prevention
Bavarian Nordic; Kinshasa School of Public Health; Ministry of Public Health,...

Active, not recruiting

JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo

Monkeypox Virus Infection

Congo, The Democratic Republic of the
National Institute of Allergy and Infectious Diseases...
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Active, not recruiting

Partnership for Research on Ebola VACcinations (PREVAC)

Ebola Virus Disease

Guinea, Liberia, Mali, Sierra Leone
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Follow-up of People at Risk of Monkeypox Infection: a Prospective Cohort Study (MonkeyVax)

Monkey Pox | Monkey Diseases

France
Bavarian Nordic

Completed

MVA-BN-RSV Vaccine Trial

Respiratory Syncytial Virus Infections

United States, Germany
Janssen Vaccines & Prevention B.V.
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Completed

A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

Ebola Virus Disease

Guinea, Sierra Leone
Janssen Vaccines & Prevention B.V.
Bavarian Nordic GmbH

Terminated

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Hemorrhagic Fever, Ebola

France, United Kingdom, Kenya, United States, Uganda, Burkina Faso, Tanzania
National Cancer Institute (NCI)

Active, not recruiting

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

Metastatic Cancer | Solid Tumors

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Ebola

United States
London School of Hygiene and Tropical Medicine
University of Sierra Leone; Janssen Vaccines & Prevention B.V.

Active, not recruiting

Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

Infections | RNA Virus Infections | Virus Diseases | Mononegavirales Infections | Hemorrhagic Fevers, Viral | Hemorrhagic Fever, Ebola | Filoviridae Infections | Physiological Effects of Drugs | Vaccines | Ebola | Immunologic Factors

Sierra Leone
National Cancer Institute (NCI)

Active, not recruiting

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Solid Tumor | Prostate Cancer | Advanced Solid Tumor | Metastatic Prostate Cancer | Prostate Neoplasm

United States
Boris Juelg, MD PhD
National Institute of Allergy and Infectious Diseases (NIAID); The University... and other collaborators

Recruiting

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Acquired Immunodeficiency Syndrome | Sexually Transmitted Diseases, Viral | Retroviridae Infections | HIV | Immunologic Deficiency Syndrome, Acquired

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

HIV Infections

Uganda, United States, Kenya, Tanzania
University of Oxford

Completed

The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV

HIV Infections | Tuberculosis

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Cytomegalovirus... and other conditions

United States
Federal Budgetary Research Institution State Research...

Completed

Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years

Smallpox | Monkeypox | Cowpox | Vaccinia Virus Infection

Russian Federation
Emergent BioSolutions

Completed

Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Smallpox

United States
Bristol-Myers Squibb

Completed

A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers

HIV Infections

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal Carcinoma

United States
University of Oxford
Medical Research Council

Completed

Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines

TB

Gambia
National Institute of Allergy and Infectious Diseases...

Withdrawn

Evaluating the Safety and Immune Response of DNA/MVA Vaccines in HIV-1-Infected Young Adults Taking Anti-HIV Medications

HIV Infections
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

Hematopoietic Cell Transplant Recipient | Cytomegaloviral Infection

United States
Sanofi Pasteur, a Sanofi Company

Terminated

Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Smallpox

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus

Cytomegalovirus Infection | Healthy, no Evidence of Disease

United States
University of Oxford

Completed

A Study of the Safety and Effectiveness of Two New Malaria Vaccines

Malaria

United Kingdom
VaxGen

Unknown

Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Early Immune Responses to Vaccination - A Substudy to HVTN 205

HIV Infections

United States
University of Oxford
University of Cape Town

Completed

A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both

HIV Infections | TB

South Africa
Crucell Holland BV

Completed

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Healthy

United States
National Cancer Institute (NCI)

Recruiting

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

Lynch Syndrome

United States, Puerto Rico
GeoVax, Inc.
National Cancer Institute (NCI); City of Hope Medical Center

Active, not recruiting

A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

COVID-19 Infection

United States
GeoVax, Inc.
National Cancer Institute (NCI)

Recruiting

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Lymphoma | Leukemia | Plasma Cell Myeloma | Hematopoietic and Lymphoid System Neoplasm | COVID-19 Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

APSV in Vaccinia Naive Adults

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

HIV Infections

United States, Peru
National Institute of Allergy and Infectious Diseases...

Withdrawn

CS DNA MVA Trial in Mampong, Ghana

Plasmodium Falciparum Malaria

Ghana, United States
Seoul National University Hospital
HK inno.N Corporation

Completed

Safety and Immunogenicity of CJ-50300

Smallpox

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

HIV Infections

United States, Peru

Search clinical trials for: MVA (smallpox vaccine)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations